Perttu Lahtinen1,2, Jonna Jalanka3, Anna Hartikainen3, Eero Mattila4, Markku Hillilä2,5, Jari Punkkinen6, Jari Koskenpato7, Veli-Jukka Anttila2,4, Jyrki Tillonen1, Reetta Satokari3, Perttu Arkkila2,8. 1. Department of Gastroenterology, Päijät-Häme Central Hospital, Lahti, Finland. 2. Faculty of Medicine, University of Helsinki, Helsinki, Finland. 3. Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. 4. Department of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland. 5. Department of Gastroenterology, Helsinki University Hospital, Espoo, Finland. 6. Department of Gastroenterology, Porvoo Hospital, Porvoo, Finland. 7. Department of Gastroenterology, Aava Medical Centre, Helsinki, Finland. 8. Department of Gastroenterology, Helsinki University Hospital, Helsinki, Finland.
Abstract
BACKGROUND:Irritable bowel syndrome (IBS) has been associated with microbial dysbiosis. AIM: To investigate the efficacy of faecal microbiota transplantation (FMT) in the treatment of IBS. METHODS:Forty-nine IBS patients were randomised to receive autologous or allogenic FMT via colonoscopy. The primary endpoint was a sustained, minimum of 50-point, reduction in the IBS Symptom Severity Score. The secondary outcomes were levels of anxiety and depression, changes in quality of life, gut microbiota and faecal water content as assessed with validated questionnaires, intestinal microbiota composition and stool dry weight. RESULTS: The primary endpoint was not achieved in either group. However, there was a transient reduction in the mean IBS Symptom Severity Score in the FMT group at 12 weeks after treatment as compared to baseline (P = 0.01). The groups did not differ in the number of patients achieving clinical response at 12 weeks. In the FMT-treated patients, microbial composition had changed to resemble that of the donor and the stool water content decreased significantly compared to baseline. The depression score decreased in patients with a reduction in IBS symptoms after FMT, but not in those placebo-treated patients who experienced a reduction in IBS symptoms. CONCLUSIONS:FMT provided only a transient relief of symptoms, although it induced a sustained alteration in the microbiota of IBS patients. Therefore, FMT delivered by a single infusion via colonoscopy cannot be recommended as a treatment for IBS in clinical practice. ClinicalTrials.Org, Trial registration number: NCT03561519.
RCT Entities:
BACKGROUND:Irritable bowel syndrome (IBS) has been associated with microbial dysbiosis. AIM: To investigate the efficacy of faecal microbiota transplantation (FMT) in the treatment of IBS. METHODS: Forty-nine IBS patients were randomised to receive autologous or allogenic FMT via colonoscopy. The primary endpoint was a sustained, minimum of 50-point, reduction in the IBS Symptom Severity Score. The secondary outcomes were levels of anxiety and depression, changes in quality of life, gut microbiota and faecal water content as assessed with validated questionnaires, intestinal microbiota composition and stool dry weight. RESULTS: The primary endpoint was not achieved in either group. However, there was a transient reduction in the mean IBS Symptom Severity Score in the FMT group at 12 weeks after treatment as compared to baseline (P = 0.01). The groups did not differ in the number of patients achieving clinical response at 12 weeks. In the FMT-treated patients, microbial composition had changed to resemble that of the donor and the stool water content decreased significantly compared to baseline. The depression score decreased in patients with a reduction in IBS symptoms after FMT, but not in those placebo-treated patients who experienced a reduction in IBS symptoms. CONCLUSIONS: FMT provided only a transient relief of symptoms, although it induced a sustained alteration in the microbiota of IBS patients. Therefore, FMT delivered by a single infusion via colonoscopy cannot be recommended as a treatment for IBS in clinical practice. ClinicalTrials.Org, Trial registration number: NCT03561519.
Authors: Jakub Hurych; Jiri Vejmelka; Lucie Hlinakova; Lenka Kramna; Vladyslav Larionov; Michal Kulich; Ondrej Cinek; Pavel Kohout Journal: BMJ Open Date: 2022-06-27 Impact factor: 3.006
Authors: Ivana Mikolašević; Goran Hauser; Maja Abram; Tajana Filipec Kanižaj; Marija Radić; Irena Krznarić Zrnić Journal: Croat Med J Date: 2021-02-28 Impact factor: 1.351
Authors: Mark Hofmeister; Fiona Clement; Scott Patten; Joyce Li; Laura E Dowsett; Brenlea Farkas; Liza Mastikhina; Oluwaseun Egunsola; Ruth Diaz; Noah C A Cooke; Valerie H Taylor Journal: CMAJ Open Date: 2021-12-21
Authors: Patrick Denis Browne; Frederik Cold; Andreas Munk Petersen; Sofie Ingdam Halkjær; Alice Højer Christensen; Stig Günther; Lars Hestbjerg Hansen Journal: Gut Microbes Date: 2021 Jan-Dec
Authors: Laura Koskenvuo; Pipsa Lunkka; Pirita Varpe; Marja Hyöty; Reetta Satokari; Carola Haapamäki; Anna Lepistö; Ville Sallinen Journal: BMJ Open Date: 2021-07-09 Impact factor: 2.692
Authors: Josbert J Keller; Rogier E Ooijevaar; Christian L Hvas; Elisabeth M Terveer; Simone C Lieberknecht; Christoph Högenauer; Perttu Arkkila; Harry Sokol; Oleksiy Gridnyev; Francis Mégraud; Patrizia K Kump; Radislav Nakov; Simon D Goldenberg; Reetta Satokari; Sergiy Tkatch; Maurizio Sanguinetti; Giovanni Cammarota; Andrey Dorofeev; Olena Gubska; Gianluca Laniro; Eero Mattila; Ramesh P Arasaradnam; Shiv K Sarin; Ajit Sood; Lorenza Putignani; Laurent Alric; Simon M D Baunwall; Juozas Kupcinskas; Alexander Link; Abraham G Goorhuis; Hein W Verspaget; Cyriel Ponsioen; Georgina L Hold; Herbert Tilg; Zain Kassam; Ed J Kuijper; Antonio Gasbarrini; Chris J J Mulder; Horace R T Williams; Maria J G T Vehreschild Journal: United European Gastroenterol J Date: 2021-03-09 Impact factor: 4.623